BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 34247183)

  • 1. Identification of CXCL13 as an Immune-Related Biomarker Associated with Tumorigenesis and Prognosis in Cutaneous Melanoma Patients.
    Si Z; Hu H
    Med Sci Monit; 2021 Jul; 27():e932052. PubMed ID: 34247183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of immune-related biomarkers associated with tumorigenesis and prognosis in cutaneous melanoma patients.
    Huang B; Han W; Sheng ZF; Shen GL
    Cancer Cell Int; 2020; 20():195. PubMed ID: 32508531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of CXCL13 as a potential biomarker in clear cell renal cell carcinoma via comprehensive bioinformatics analysis.
    Xu T; Ruan H; Song Z; Cao Q; Wang K; Bao L; Liu D; Tong J; Yang H; Chen K; Zhang X
    Biomed Pharmacother; 2019 Oct; 118():109264. PubMed ID: 31390578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of CXCL13 and Immune Cell Infiltration Signature in Clear Cell Renal Cell Carcinoma.
    Jiao F; Sun H; Yang Q; Sun H; Wang Z; Liu M; Chen J
    Int J Med Sci; 2020; 17(11):1610-1624. PubMed ID: 32669964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive analysis of the prognosis and biological significance for IFIT family in skin cutaneous melanoma.
    Jiang Y; Zhang C; Zhang J; Han D; Shi X
    Int Immunopharmacol; 2021 Dec; 101(Pt A):108344. PubMed ID: 34763233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aspartate beta-hydroxylase domain containing 1 as a prognostic marker associated with immune infiltration in skin cutaneous melanoma.
    Sun S; Deng M; Wen J; Chen X; Xu J; Liu Y; Wan H; Wang J; Yan L; He Y; Xu Y
    BMC Cancer; 2023 Mar; 23(1):292. PubMed ID: 37004045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The nucleosome remodeling and deacetylase complex has prognostic significance and associates with immune microenvironment in skin cutaneous melanoma.
    Liu X; Wang J
    Int Immunopharmacol; 2020 Nov; 88():106887. PubMed ID: 32799111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening and identification of potential prognostic biomarkers in metastatic skin cutaneous melanoma by bioinformatics analysis.
    Sheng Z; Han W; Huang B; Shen G
    J Cell Mol Med; 2020 Oct; 24(19):11613-11618. PubMed ID: 32869947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis on tumor immune microenvironment and construction of a prognosis model for immune-related skin cutaneous melanoma.
    Wu M; Wang Z; Zhang J
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 May; 48(5):671-681. PubMed ID: 37539569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PMEL as a Prognostic Biomarker and Negatively Associated With Immune Infiltration in Skin Cutaneous Melanoma (SKCM).
    Zhang S; Chen K; Liu H; Jing C; Zhang X; Qu C; Yu S
    J Immunother; 2021 Jul-Aug 01; 44(6):214-223. PubMed ID: 34028390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a novel tumour microenvironment-based prognostic biomarker in skin cutaneous melanoma.
    Yang RH; Liang B; Li JH; Pi XB; Yu K; Xiang SJ; Gu N; Chen XD; Zhou ST
    J Cell Mol Med; 2021 Dec; 25(23):10990-11001. PubMed ID: 34755462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Data mining of immune-related prognostic genes in metastatic melanoma microenvironment.
    Han W; Huang B; Zhao XY; Shen GL
    Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33169786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Landscape of the Tumor Microenvironment in Skin Cutaneous Melanoma Reveals a Prognostic and Immunotherapeutically Relevant Gene Signature.
    Zhou S; Sun Y; Chen T; Wang J; He J; Lyu J; Shen Y; Chen X; Yang R
    Front Cell Dev Biol; 2021; 9():739594. PubMed ID: 34660598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer.
    Yang M; Lu J; Zhang G; Wang Y; He M; Xu Q; Xu C; Liu H
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression and immune infiltration in melanoma patients with different mutation burden.
    Wang L; Chen F; Liu R; Shi L; Zhao G; Yan Z
    BMC Cancer; 2021 Apr; 21(1):379. PubMed ID: 33836680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of differential gene immune infiltration and clinical characteristics of skin cutaneous melanoma based on systems biology and drug repositioning methods to identify drug candidates for skin cutaneous melanoma.
    Long S; Xu J; Huang H
    Naunyn Schmiedebergs Arch Pharmacol; 2023 Oct; 396(10):2427-2447. PubMed ID: 37086280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TREM2 as a Potential Immune-Related Biomarker of Prognosis in Patients with Skin Cutaneous Melanoma Microenvironment.
    Zhu X; Zeng Z; Chen M; Chen X; Hu D; Jiang W; Du M; Chen T; Chen T; Liao W; Zhang C; Qu Y; Pan W
    Dis Markers; 2023; 2023():8101837. PubMed ID: 36741909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptome Network Analysis Identifies CXCL13-CXCR5 Signaling Modules in the Prostate Tumor Immune Microenvironment.
    Ohandjo AQ; Liu Z; Dammer EB; Dill CD; Griffen TL; Carey KM; Hinton DE; Meller R; Lillard JW
    Sci Rep; 2019 Oct; 9(1):14963. PubMed ID: 31628349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of SRGN in the survival and immune infiltrates of skin cutaneous melanoma (SKCM) and SKCM-metastasis patients.
    Wang X; Xiong H; Liang D; Chen Z; Li X; Zhang K
    BMC Cancer; 2020 May; 20(1):378. PubMed ID: 32370744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of immune subtypes based on immunogenomic profiling identifies prognostic signature for cutaneous melanoma.
    Hu B; Wei Q; Zhou C; Ju M; Wang L; Chen L; Li Z; Wei M; He M; Zhao L
    Int Immunopharmacol; 2020 Dec; 89(Pt A):107162. PubMed ID: 33168410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.